Intravenous palivizumab in respiratory syncytial virus infection after hematopoietic stem cell transplant in children

Respiratory syncytial virus (RSV) infection can cause lower respiratory tract disease and mortality in pediatric hematopoietic stem cell transplant (HSCT) recipients. We report two children who underwent HSCT and developed RSV infection simultaneously at the Bone Marrow Transplant Unit. The treatment with intravenous palivizumab was provided and sequential viral loads were measured in nasopharyngeal (NP) and whole blood samples. To our knowledge, this is the first report where RSV loads were measured in parallel (NP and blood), before and after palivizumab, in correlation with a favorable clinical outcome in both cases.

[1]  J. Pollard,et al.  Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children , 2016, Influenza and other respiratory viruses.

[2]  P. Schnitzler,et al.  Long-Term Shedding of Influenza Virus, Parainfluenza Virus, Respiratory Syncytial Virus and Nosocomial Epidemiology in Patients with Hematological Disorders , 2016, PloS one.

[3]  P. Piedra,et al.  Infection with novel respiratory syncytial virus genotype Ontario (ON1) in adult hematopoietic cell transplant recipients, Texas, 2011-2013. , 2015, The Journal of infectious diseases.

[4]  W. Leisenring,et al.  Respiratory Syncytial Virus Lower Respiratory Disease in Hematopoietic Cell Transplant Recipients: Viral RNA Detection in Blood, Antiviral Treatment, and Clinical Outcomes , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Pearce,et al.  The Use of Intravenous Palivizumab for Treatment of Persistent RSV Infection in Children With Leukemia , 2012, Pediatrics.

[6]  O. Ramilo,et al.  Respiratory Syncytial Virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice , 2010, Respiratory research.

[7]  M. Barreto,et al.  The presence of serum anti-Ascaris lumbricoides IgE antibodies and of Trichuris trichiura infection are risk factors for wheezing and/or atopy in preschool-aged Brazilian children , 2010, Respiratory research.

[8]  R. Frenck,et al.  From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. , 2009, Pediatrics.

[9]  O. Ramilo,et al.  Intravenous Palivizumab and Ribavirin Combination for Respiratory Syncytial Virus Disease in High-Risk Pediatric Patients , 2007, The Pediatric infectious disease journal.

[10]  R. Porcher,et al.  Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Sierra,et al.  Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[13]  O. Ramilo,et al.  Anti-Respiratory Syncytial Virus (RSV) Neutralizing Antibody Decreases Lung Inflammation, Airway Obstruction, and Airway Hyperresponsiveness in a Murine RSV Model , 2004, Antimicrobial Agents and Chemotherapy.

[14]  C B Hall,et al.  Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. , 1998, The Journal of general virology.